289 related articles for article (PubMed ID: 36771408)
1. The Impact of Phytochemicals in Obesity-Related Metabolic Diseases: Focus on Ceramide Metabolism.
Kim E; Jeon S
Nutrients; 2023 Jan; 15(3):. PubMed ID: 36771408
[TBL] [Abstract][Full Text] [Related]
2. Ceramides - Lipotoxic Inducers of Metabolic Disorders.
Chaurasia B; Summers SA
Trends Endocrinol Metab; 2015 Oct; 26(10):538-550. PubMed ID: 26412155
[TBL] [Abstract][Full Text] [Related]
3. The Lard Works in Mysterious Ways: Ceramides in Nutrition-Linked Chronic Disease.
Nicholson RJ; Norris MK; Poss AM; Holland WL; Summers SA
Annu Rev Nutr; 2022 Aug; 42():115-144. PubMed ID: 35584813
[TBL] [Abstract][Full Text] [Related]
4. A ceramide-centric view of insulin resistance.
Chavez JA; Summers SA
Cell Metab; 2012 May; 15(5):585-94. PubMed ID: 22560211
[TBL] [Abstract][Full Text] [Related]
5. Contribution of specific ceramides to obesity-associated metabolic diseases.
Hammerschmidt P; Brüning JC
Cell Mol Life Sci; 2022 Jul; 79(8):395. PubMed ID: 35789435
[TBL] [Abstract][Full Text] [Related]
6. Ceramides in Metabolism: Key Lipotoxic Players.
Chaurasia B; Summers SA
Annu Rev Physiol; 2021 Feb; 83():303-330. PubMed ID: 33158378
[TBL] [Abstract][Full Text] [Related]
7. Targeting sphingolipid metabolism in the treatment of obesity/type 2 diabetes.
Bellini L; Campana M; Mahfouz R; Carlier A; Véret J; Magnan C; Hajduch E; Le Stunff H
Expert Opin Ther Targets; 2015; 19(8):1037-50. PubMed ID: 25814122
[TBL] [Abstract][Full Text] [Related]
8. Sphingolipid Metabolism: New Insight into Ceramide-Induced Lipotoxicity in Muscle Cells.
Bandet CL; Tan-Chen S; Bourron O; Le Stunff H; Hajduch E
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30678043
[TBL] [Abstract][Full Text] [Related]
9. Serum sphingolipids: relationships to insulin sensitivity and changes with exercise in humans.
Bergman BC; Brozinick JT; Strauss A; Bacon S; Kerege A; Bui HH; Sanders P; Siddall P; Kuo MS; Perreault L
Am J Physiol Endocrinol Metab; 2015 Aug; 309(4):E398-408. PubMed ID: 26126684
[TBL] [Abstract][Full Text] [Related]
10. Sphingolipids: agents provocateurs in the pathogenesis of insulin resistance.
Lipina C; Hundal HS
Diabetologia; 2011 Jul; 54(7):1596-607. PubMed ID: 21468641
[TBL] [Abstract][Full Text] [Related]
11. Targeting ceramide metabolism in obesity.
Aburasayn H; Al Batran R; Ussher JR
Am J Physiol Endocrinol Metab; 2016 Aug; 311(2):E423-35. PubMed ID: 27382035
[TBL] [Abstract][Full Text] [Related]
12. New role for ceramide in hypoxia and insulin resistance.
Xia QS; Lu FE; Wu F; Huang ZY; Dong H; Xu LJ; Gong J
World J Gastroenterol; 2020 May; 26(18):2177-2186. PubMed ID: 32476784
[TBL] [Abstract][Full Text] [Related]
13. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.
Holland WL; Summers SA
Endocr Rev; 2008 Jun; 29(4):381-402. PubMed ID: 18451260
[TBL] [Abstract][Full Text] [Related]
14. Ceramide Acyl Chain Length and Its Relevance to Intracellular Lipid Regulation.
Ho QWC; Zheng X; Ali Y
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077094
[TBL] [Abstract][Full Text] [Related]
15. Fat-Secreted Ceramides Regulate Vascular Redox State and Influence Outcomes in Patients With Cardiovascular Disease.
Akawi N; Checa A; Antonopoulos AS; Akoumianakis I; Daskalaki E; Kotanidis CP; Kondo H; Lee K; Yesilyurt D; Badi I; Polkinghorne M; Akbar N; Lundgren J; Chuaiphichai S; Choudhury R; Neubauer S; Channon KM; Torekov SS; Wheelock CE; Antoniades C
J Am Coll Cardiol; 2021 May; 77(20):2494-2513. PubMed ID: 34016263
[TBL] [Abstract][Full Text] [Related]
16. Ceramides are necessary and sufficient for diet-induced impairment of thermogenic adipocytes.
Chaurasia B; Ying L; Talbot CL; Maschek JA; Cox J; Schuchman EH; Hirabayashi Y; Holland WL; Summers SA
Mol Metab; 2021 Mar; 45():101145. PubMed ID: 33352310
[TBL] [Abstract][Full Text] [Related]
17. Effects of Isocaloric Fructose Restriction on Ceramide Levels in Children with Obesity and Cardiometabolic Risk: Relation to Hepatic De Novo Lipogenesis and Insulin Sensitivity.
Olson E; Suh JH; Schwarz JM; Noworolski SM; Jones GM; Barber JR; Erkin-Cakmak A; Mulligan K; Lustig RH; Mietus-Snyder M
Nutrients; 2022 Mar; 14(7):. PubMed ID: 35406045
[TBL] [Abstract][Full Text] [Related]
18. Sphingolipid content of human adipose tissue: relationship to adiponectin and insulin resistance.
Blachnio-Zabielska AU; Koutsari C; Tchkonia T; Jensen MD
Obesity (Silver Spring); 2012 Dec; 20(12):2341-7. PubMed ID: 22677645
[TBL] [Abstract][Full Text] [Related]
19. Sphingolipids as a Culprit of Mitochondrial Dysfunction in Insulin Resistance and Type 2 Diabetes.
Roszczyc-Owsiejczuk K; Zabielski P
Front Endocrinol (Lausanne); 2021; 12():635175. PubMed ID: 33815291
[TBL] [Abstract][Full Text] [Related]
20. Chronic Cannabidiol Administration Attenuates Skeletal Muscle De Novo Ceramide Synthesis Pathway and Related Metabolic Effects in a Rat Model of High-Fat Diet-Induced Obesity.
Bielawiec P; Harasim-Symbor E; Konstantynowicz-Nowicka K; Sztolsztener K; Chabowski A
Biomolecules; 2020 Aug; 10(9):. PubMed ID: 32859125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
